Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

AstraZeneca to share latest data with panel after U.S. trial data doubts

FILE PHOTO: Vials of the AstraZeneca coronavirus disease (COVID-19) vaccine are seen, as AstraZeneca vaccinations resume after a brief pause in their use over concern for possible connection to blood clots, in Milan, Italy, March 19, 2021. REUTERS/Flavio Lo Scalzo

AstraZeneca will share primary analysis of its COVID-19 vaccine with the most up-to-date data, with an independent panel looking into its U.S. trial, the drugmaker said on Tuesday, following doubts expressed by a U.S health body over the trial data.

The Anglo-Swedish drugmaker said data presented on Monday was based on analysis with a cut-off date of Feb. 17, adding that it had reviewed the preliminary assessment of the primary analysis and found it to be consistent with the interim report.

"We will immediately engage with the independent data safety monitoring board (DSMB) .... We intend to issue results of the primary analysis within 48 hours," AstraZeneca said.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.